Acceleron Pharma Initiates Phase I Muscle Diseases Study
Posted on: Monday, 20 October 2008, 09:00 CDT
Acceleron Pharma has started a Phase I clinical study of ACE-031, its lead compound for treating diseases involving the loss of muscle mass and function.
The Phase I trial is a randomized, placebo-controlled single-dose, dose-escalating study to evaluate the safety and pharmacokinetics of ACE-031. This clinical trial is the first-in-human study in the global development of ACE-031 and will be conducted in Canada, said Acceleron Pharma.
According to the company, ACE-031, a soluble molecule based on the activin receptor type IIB, is a biologic therapeutic that inhibits signaling through the ActRIIB receptor. By blocking signaling though ActRIIB, ACE-031 increases muscle mass and strength.
Matthew Sherman, chief medical officer of Acceleron, said: "There is a tremendous unmet medical need to treat patients suffering from a wide array of diseases involving the loss of muscle strength and function. ACE-031 has the potential to be a very important new approach to treat these serious and life-threatening conditions."
Source: Datamonitor
Related Articles
- Acceleron Initiates Phase 1 Clinical Trial for ACE-031 to Treat Diseases Involving Muscle Loss
- Celgene Corporation and Acceleron Pharma Initiate Phase 2 Study of ACE-011 in Patients With Multiple Myeloma
- Acceleron Pharma's ACE-031 Increases Muscle Mass In a Preclinical Model of Glucocorticoid-Induced Muscle Loss
- Acceleron Pharma Appoints Niels Borgstein, M.D. As Vice President, Medical Research
- Weight Training May Be 'Fountain of Youth' for Aging Muscles: Study
- Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in Preclinical Studies
- ACE Inhibitors Are Studied
- Akt2 Is Essential for the Full Effect of Calorie Restriction on Insulin-Stimulated Glucose Uptake in Skeletal Muscle
- How Blood Pressure Pill Prevents Heart Attacks
 |
 |
User Comments (0)
RSS Feeds